IN THE ERA OF INNOVATION AND PERSONALIZED MEDICINE: A CLINICALCASE OF A PATIENT WITH NON-SMALL CELL LUNG CANCERWITH AN ACTIVATING MUTATION IN THE EGFR GENE. BRIEFOVERVIEW OF THERAPEUTIC OPTIONS

Abstract

The existence of a unique genetic profile for each tumor type has led to the introduction of an individualized approach to therapeutic decision making, marking the era of personalized medicine. Nowadays, the administration of tyrosine kinase inhibitors (TKIs) is standard in the treatment of non-small cell lung cancer (NSCLC). Elucidating the role of the epidermal growth factor receptor (EGFR) has given us new innovative treatment options and approaches with better outcomes.